XML 18 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Revenues        
Revenues $ 52,804 $ 0 $ 85,348 $ 0
Expenses        
Cost of sales - product (6,256)   (10,806)  
Research and development (164,251) (47,245) (273,951) (90,018)
Selling, general and administrative (45,160) (10,777) (74,075) (19,546)
Amortization of intangible assets (187) 0 (375) 0
Total expenses (215,854) (58,022) (359,207) (109,564)
Loss from operations (163,050) (58,022) (273,859) (109,564)
Interest income (expense), net 1,892 (1,982) 3,444 (1,796)
Other income (expense), net 75 (475) 804 438
Loss before income tax expense (161,083) (60,479) (269,611) (110,922)
Income tax benefit (expense) 3,368 (201) 6,780 (381)
Net loss (157,715) (60,680) (262,831) (111,303)
Less: net loss attributable to noncontrolling interests (828) (135) (1,348) (135)
Net loss attributable to BeiGene, Ltd. $ (156,887) $ (60,545) $ (261,483) $ (111,168)
Net loss per share attributable to BeiGene, Ltd.        
Basic and diluted (in dollars per share) $ (0.22) $ (0.12) $ (0.38) $ (0.22)
Weighted-average shares used in net loss per share calculation        
Basic and diluted (in shares) 698,506,891 517,663,736 684,586,086 517,054,109
Net loss per American Depositary Share (“ADS”)        
Basic and diluted (in dollars per share) $ (2.92) $ (1.52) $ (4.97) $ (2.80)
Weighted-average ADSs used in net loss per share calculation        
Basic and diluted (in ADSs) (in shares) 53,731,299 39,820,287 52,660,468 39,773,393
Product        
Revenues        
Revenues $ 31,426 $ 0 $ 54,676 $ 0
Collaboration        
Revenues        
Revenues $ 21,378 $ 0 $ 30,672 $ 0